What is Tzield?
In autoimmune Type 1 diabetes (T1D), the body’s immune system mistakenly attacks healthy cells in the pancreas called beta cells. Beta cells produce a hormone called insulin which helps your body convert sugar from your blood
into energy.1,2
Tzield helps to preserve the function of beta cells so that they can keep producing insulin. This may slow the progression from Stage 2 T1D to Stage 3 T1D.3
Who is it for?
Tzield is a medicine used to delay the start of Stage 3 T1D in adults and children aged 8 years and older who have Stage 2 T1D.4
Your doctor has prescribed you Tzield because there is evidence of Stage 2 T1D, which
is defined as having:3
Two or more T1D autoantibodies
Abnormal blood sugar levels
No evidence of Type 2 diabetes
Tzield is a medicine used to delay the start of Stage 3 Type 1 diabetes. This condition happens when the body cannot make enough insulin on its own and may need insulin injections. This medicine is used in adults and children aged 8 years and older who have Stage 2 Type 1 diabetes.4
If you have any questions on how Tzield works or about your treatment with Tzield, ask your doctor.
This website is not intended to be a substitute for medical advice. Please refer to the Patient information leaflet and the Patient Guide for full safety information. You may have received these items from your doctor already.
The contents of this website have been developed and funded by Sanofi.
References:
- Diabetes UK. What causes type 1 diabetes. Available at: https://www.diabetes.org.uk/about-diabetes/type-1-diabetes/causes. Accessed: November 2025.
- Diabetes UK. What is insulin? Available at: https://www.diabetes.org.uk/about-diabetes/looking-after-diabetes/treatments/insulin/what-is-insulin. Accessed: November 2025.
- TZIELD® (teplizumab) UK Summary of Product Characteristics. Accessed: November 2025.
- TZIELD® (teplizumab) UK Patient Information Leaflet. Accessed: November 2025.
Reporting side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple app Store.
Alternatively, you can report side effects to Sanofi on Tel: 0800 0902 314 or send via email to UK-drugsafety@sanofi.com. By reporting side effects, you can help provide more information on the safety of this medicine.
▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects that you may get. See www.mhra.gov.uk/yellowcard for how to report side effects.
© 2025 Sanofi. All rights reserved. MAT-XU-2501101 (V1.0) | November 2025
Welcome to Tzield
Welcome to Tzield
This website and its contents have been developed by Sanofi for patients in the United Kingdom who have been prescribed Tzield.
In order to proceed into the website, please confirm that you are, or you care for, a patient in the United Kingdom prescribed Tzield by clicking the confirmation button below.
MAT-XU-2503330 (V1.0) - Date of preparation: November 2025